For: | Meng QB, Peng JJ, Qu ZW, Zhu XM, Wen Z, Kang WM. Eukaryotic initiation factor 5A2 and human digestive system neoplasms. World J Gastrointest Oncol 2019; 11(6): 449-458 [PMID: 31236196 DOI: 10.4251/wjgo.v11.i6.449] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v11/i6/449.htm |
Number | Citing Articles |
1 |
Renrui Wu, Qiong Zhong, Huafeng Liu, Shubin Liu. MicroRNA‐577/EIF5A2 axis suppressed the proliferation of DDP‐resistant nasopharyngeal carcinoma cells by blocking TGF‐β signaling pathway. Chemical Biology & Drug Design 2023; 102(4): 815 doi: 10.1111/cbdd.14293
|
2 |
Shimin Zhuang, Jing Xie, Jing Zhen, Liangyun Guo, Zhengdong Hong, Feihong Li, Debin Xu. The deubiquitinating enzyme ATXN3 promotes the progression of anaplastic thyroid carcinoma by stabilizing EIF5A2. Molecular and Cellular Endocrinology 2021; 537: 111440 doi: 10.1016/j.mce.2021.111440
|
3 |
Pía Loren, Nicolás Saavedra, Kathleen Saavedra, Nadine De Godoy Torso, Marília Berlofa Visacri, Patricia Moriel, Luis A. Salazar. Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.831099
|
4 |
Xiulong Zhong, Hong Xiu, Yanan Bi, Hongmei Zhang, Laizhen Chang, Huifeng Diao.
Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis
in vitro
and
in vivo
. Bioengineered 2020; 11(1): 619 doi: 10.1080/21655979.2020.1774993
|
5 |
Qi Li, Mulun Xiao, Yibo Shi, Jinhao Hu, Tianxiang Bi, Chaoliang Wang, Liang Yan, Xiaoyan Li. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08749-w
|